DUGI, KLAUS,GRAEFE-MODY, EVA ULRIKE,HARPER, RUTH,WOERLE, HANS-JUERGEN
申请号：
NZ59078709
公开号：
NZ590787A
申请日:
2009.08.05
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
Disclosed herein is the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, which is a DPP-4 inhibitor, or a pharmaceutically acceptable salt thereof, for preparing a medicament for oral administration for treating and/or preventing of metabolic diseases in patients for whom metformin therapy is inappropriate due to contraindication against metformin. Said medicament may be used in the treatment and/or prevention of type 2 diabetes mellitus in patients with at least one contraindication selected from: renal disease, renal impairment or renal dysfunction； dehydration； unstable or acute congestive heart failure； acute or chromic metabolic acidosis； and hereditary galactose intolerance. The disclosure also relates to the use of said DPP-4 inhibitor in combination with one or more further active substances selected from sulphonylureas, thiazolidinedones, glinides, alpha-glucosidase blockers, GLP-1 and GLP-1 analogues, and insulin and insulin analogues.
